EVALUATION OF ALEXITHYMIA AND ITS RELATIONSHIP WITH CLINICAL PARAMETERS IN PATIENTS WITH CHRONIC COCCYDYNIA
EVALUATION OF THE PRESENCE OF ALEXITHYMIA AND ITS RELATIONSHIP WITH CLINICAL PARAMETERS IN PATIENTS WITH CHRONIC COCCYDYNIA (>=3 MONTHS)
1 other identifier
observational
15
1 country
1
Brief Summary
This study aims to investigate the prevalence and levels of alexithymia in patients diagnosed with chronic coccydynia (tailbone pain lasting for 3 months or longer) and to explore its relationship with various clinical and psychological parameters. Chronic coccydynia can significantly impair daily activities, functionality, and reduce quality of life. Participants in this prospective, observational study will be evaluated during their routine visits to the pain management clinic. Evaluation of the participants will be performed using validated self-report questionnaires, including the Toronto Alexithymia Scale (TAS-20) for alexithymia, the Hospital Anxiety and Depression Scale (HADS) for mood symptoms, the Childhood Trauma Questionnaire (CTQ-33) for early life adverse experiences, the Visual Analog Scale (VAS) for pain intensity, and the SF-12 Health Survey for quality of life. The primary objective of the study is to determine how alexithymia relates to pain severity, duration, emotional symptoms, childhood trauma history, and overall quality of life in this specific population. The results of this pilot study may help strengthen the biopsychosocial approach in the evaluation of chronic coccydynia and optimize future multidisciplinary treatment strategies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Mar 2026
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 20, 2026
CompletedFirst Submitted
Initial submission to the registry
July 6, 2026
CompletedFirst Posted
Study publicly available on registry
July 10, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 1, 2027
July 10, 2026
July 1, 2026
12 months
July 6, 2026
July 6, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Toronto Alexithymia Scale (TAS-20) Score
A 20-item self-report questionnaire used to evaluate the presence and severity of alexithymia. It assesses three subscales: difficulty identifying feelings, difficulty describing feelings, and externally-oriented thinking. Total scores range from 20 to 100, where higher scores indicate a higher level of alexithymia.
Baseline (Single-time assessment during the clinical interview)
Secondary Outcomes (4)
Visual Analog Scale (VAS) for Pain
Baseline (Single-time assessment)
Hospital Anxiety and Depression Scale (HADS) Score
Baseline (Single-time assessment)
Childhood Trauma Questionnaire (CTQ-33) Score
Baseline (Single-time assessment)
Short Form Health Survey (SF-12) Score
Baseline (Single-time assessment)
Study Arms (1)
Chronic Coccydynia Patients
Patients aged 18 and older who present to the algology outpatient clinic with a diagnosis of chronic coccydynia lasting for 3 months or longer. Participants will undergo a single-time biopsychosocial assessment using validated psychometric scales including TAS-20, HADS, CTQ-33, VAS, and SF-12 during their routine evaluation.
Eligibility Criteria
Patients aged 18 and older who present to the algology outpatient clinic and meet the diagnostic criteria for chronic coccydynia lasting for 3 months or longer.
You may qualify if:
- Being older than 18 years of age
- Volunteering to participate in the study and providing written informed consent
- Being literate and having the mental capacity to comprehend the questionnaires
- Having no active, treated severe psychiatric disorder (such as schizophrenia or bipolar affective disorder)
You may not qualify if:
- \- Cognitive impairment or communication barriers that compromise the capacity to consent
- Active psychotic disorder or manic episode
- Suspected self-harm or suicide risk during the clinical interview
- Distinct secondary causes of pain such as malignancy, active infection, or acute fracture
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Marmara University Pendik Training and Research Hospital
Istanbul, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor, MD
Study Record Dates
First Submitted
July 6, 2026
First Posted
July 10, 2026
Study Start
March 20, 2026
Primary Completion (Estimated)
March 1, 2027
Study Completion (Estimated)
March 1, 2027
Last Updated
July 10, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will not share